$BIAF
bioAffinity Technologies, Inc.

2024 Q4 Form 10-Q Financial Statement

#000149315224045954 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $2.350M
YoY Change 682.85%
Cost Of Revenue $1.440M
YoY Change 1827.82%
Gross Profit $910.2K
YoY Change 306.75%
Gross Profit Margin 38.73%
Selling, General & Admin $2.365M
YoY Change 16.83%
% of Gross Profit 259.78%
Research & Development $274.5K
YoY Change -16.91%
% of Gross Profit 30.16%
Depreciation & Amortization $40.47K
YoY Change 72.22%
% of Gross Profit 4.45%
Operating Expenses $4.324M
YoY Change 71.71%
Operating Profit -$1.974M
YoY Change -13.97%
Interest Expense -$19.40K
YoY Change -320.83%
% of Operating Profit
Other Income/Expense, Net -$24.42K
YoY Change 144.17%
Pretax Income -$1.998M
YoY Change -12.69%
Income Tax $2.559K
% Of Pretax Income
Net Earnings -$2.001M
YoY Change -12.66%
Net Earnings / Revenue -85.13%
Basic Earnings Per Share -$0.16
Diluted Earnings Per Share -$0.16
COMMON SHARES
Basic Shares Outstanding 15.58M shares 13.45M shares
Diluted Shares Outstanding 12.39M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $756.6K
YoY Change -83.22%
Cash & Equivalents $800.0K
Short-Term Investments
Other Short-Term Assets $440.0K
YoY Change 15.8%
Inventory $25.36K
Prepaid Expenses
Receivables $1.278M
Other Receivables $49.19K
Total Short-Term Assets $2.549M
YoY Change -57.59%
LONG-TERM ASSETS
Property, Plant & Equipment $418.2K
YoY Change -18.35%
Goodwill $1.404M
YoY Change 22.28%
Intangibles $789.7K
YoY Change -6.88%
Long-Term Investments
YoY Change
Other Assets $19.68K
YoY Change 22.52%
Total Long-Term Assets $4.003M
YoY Change -4.22%
TOTAL ASSETS
Total Short-Term Assets $2.549M
Total Long-Term Assets $4.003M
Total Assets $6.552M
YoY Change -35.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $782.9K
YoY Change -5.37%
Accrued Expenses $904.3K
YoY Change 40.46%
Deferred Revenue
YoY Change
Short-Term Debt $260.0K
YoY Change
Long-Term Debt Due $654.9K
YoY Change 81.91%
Total Short-Term Liabilities $2.491M
YoY Change 27.19%
LONG-TERM LIABILITIES
Long-Term Debt $564.7K
YoY Change -39.28%
Other Long-Term Liabilities $375.1K
YoY Change 21.01%
Total Long-Term Liabilities $939.8K
YoY Change -24.21%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.491M
Total Long-Term Liabilities $939.8K
Total Liabilities $3.431M
YoY Change 7.37%
SHAREHOLDERS EQUITY
Retained Earnings -$50.70M
YoY Change 20.14%
Common Stock $90.06K
YoY Change 39.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.121M
YoY Change
Total Liabilities & Shareholders Equity $6.552M
YoY Change -35.7%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$2.001M
YoY Change -12.66%
Depreciation, Depletion And Amortization $40.47K
YoY Change 72.22%
Cash From Operating Activities -$1.709M
YoY Change 11.71%
INVESTING ACTIVITIES
Capital Expenditures $9.410K
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$9.410K
YoY Change -99.57%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.674M
YoY Change -3447.84%
NET CHANGE
Cash From Operating Activities -1.709M
Cash From Investing Activities -9.410K
Cash From Financing Activities 1.674M
Net Change In Cash -44.72K
YoY Change -98.81%
FREE CASH FLOW
Cash From Operating Activities -$1.709M
Capital Expenditures $9.410K
Free Cash Flow -$1.719M
YoY Change 12.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5211056
dei Entity Address Address Line1
EntityAddressAddressLine1
3300 Nacogdoches Road
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 216
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15584635 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.007
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13424648 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13424648 shares
dei Amendment Flag
AmendmentFlag
false
dei Entity Central Index Key
EntityCentralIndexKey
0001712762
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-41463
dei Entity Registrant Name
EntityRegistrantName
bioAffinity Technologies, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address City Or Town
EntityAddressCityOrTown
San Antonio
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
78217
dei City Area Code
CityAreaCode
(210)
dei Local Phone Number
LocalPhoneNumber
698-5334
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
8098348 usd
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
usd
CY2023Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
usd
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
usd
us-gaap Operating Lease Payments
OperatingLeasePayments
usd
CY2024Q3 BIAF Finance Lease Liability Payments Due Year Three And Thereafter
FinanceLeaseLiabilityPaymentsDueYearThreeAndThereafter
usd
dei Document Type
DocumentType
10-Q
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
756580 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2821570 usd
CY2024Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1327168 usd
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
811674 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
25363 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
18484 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
440027 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
321017 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
2549138 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
3972745 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
418190 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
458633 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
493687 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
370312 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
877115 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1165844 usd
CY2024Q3 us-gaap Goodwill
Goodwill
1404486 usd
CY2023Q4 us-gaap Goodwill
Goodwill
1404486 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
789722 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
833472 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19676 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
16060 usd
CY2024Q3 us-gaap Assets
Assets
6552014 usd
CY2023Q4 us-gaap Assets
Assets
8221552 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
782937 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
604789 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
904252 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1149811 usd
CY2024Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
24404 usd
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
33058 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
124710 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
94708 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
387780 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
365463 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
267081 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2491164 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2247829 usd
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
543007 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
835467 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
375139 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
283001 usd
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
21679 usd
CY2024Q3 us-gaap Liabilities
Liabilities
3430989 usd
CY2023Q4 us-gaap Liabilities
Liabilities
3366297 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.007
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9394610 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9394610 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
90064 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
65762 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
53708374 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
49393972 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50677413 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44604479 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3121025 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4855255 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6552014 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8221552 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2350386 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
298484 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7154429 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
319143 usd
CY2024Q3 BIAF Direct Costs And Expenses
DirectCostsAndExpenses
1440158 usd
CY2023Q3 BIAF Direct Costs And Expenses
DirectCostsAndExpenses
74704 usd
BIAF Direct Costs And Expenses
DirectCostsAndExpenses
4421309 usd
BIAF Direct Costs And Expenses
DirectCostsAndExpenses
76025 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
274497 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
330376 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1070569 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1035118 usd
CY2024Q3 BIAF Clinical Development Expense
ClinicalDevelopmentExpense
93705 usd
CY2023Q3 BIAF Clinical Development Expense
ClinicalDevelopmentExpense
106422 usd
BIAF Clinical Development Expense
ClinicalDevelopmentExpense
194127 usd
BIAF Clinical Development Expense
ClinicalDevelopmentExpense
161310 usd
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2364592 usd
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2023917 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
7023311 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4576708 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
151298 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
57569 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
452005 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
100805 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
4324250 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2592988 usd
us-gaap Operating Expenses
OperatingExpenses
13161321 usd
us-gaap Operating Expenses
OperatingExpenses
5949966 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1973864 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2294504 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6006892 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5630823 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2228 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
27193 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
13541 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
109971 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
21631 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
8785 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
67430 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
11801 usd
CY2024Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
9683 usd
CY2023Q3 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
4606 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
9683 usd
us-gaap Other Nonoperating Income
OtherNonoperatingIncome
4606 usd
CY2024Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
14697 usd
CY2023Q3 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
17100 usd
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
10186 usd
us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
17100 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24417 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5914 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-54392 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
85676 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1998281 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2288590 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6061284 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5545147 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2559 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2294 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11650 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18700 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2000840 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2290884 usd
us-gaap Net Income Loss
NetIncomeLoss
-6072934 usd
us-gaap Net Income Loss
NetIncomeLoss
-5563847 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.16
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.26
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.65
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12391867 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12391867 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8696554 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8696554 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
11237324 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
11237324 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8551154 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8551154 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
4855255 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
755594 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
74899 usd
BIAF Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1343377 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2950000 usd
us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
785167 usd
us-gaap Net Income Loss
NetIncomeLoss
-6072934 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3121025 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
3433114 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
185687 usd
CY2024Q3 BIAF Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1343230 usd
CY2024Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
450000 usd
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
290167 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2000840 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3121025 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11043443 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
514313 usd
us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
1000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-5563847 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6993909 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
8098348 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
186445 usd
CY2023Q3 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
1000000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2290884 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6993909 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
6993909 usd
us-gaap Net Income Loss
NetIncomeLoss
-6072934 usd
us-gaap Net Income Loss
NetIncomeLoss
-5563847 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
452005 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
100805 usd
us-gaap Share Based Compensation
ShareBasedCompensation
755594 usd
us-gaap Share Based Compensation
ShareBasedCompensation
514313 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
515494 usd
us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
-71840 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
6879 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4368 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
122626 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-152768 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
178148 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
406836 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-245559 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-144013 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-8654 usd
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
38250 usd
BIAF Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
1235 usd
BIAF Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-5913 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5587634 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4421503 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
79082 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36344 usd
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
2186497 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-79082 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2222841 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
785167 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
2164833 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
74899 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1343377 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
251746 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
288760 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
270143 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
8433 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3601726 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-260179 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2064990 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6904523 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
2821570 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11413759 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
756580 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
4509236 usd
us-gaap Interest Paid Net
InterestPaidNet
13541 usd
us-gaap Interest Paid Net
InterestPaidNet
11801 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
11650 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
18700 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-50700000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
800000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_848_eus-gaap--UseOfEstimates_zHDwina1nNai" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_864_zl2KJRU8cYAe">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include the valuation allowance on the Company’s deferred tax assets, stock-based compensation, valuation of goodwill and intangible assets related to the business combination, allowance for contractual adjustments and discounts related to service revenues, and the useful lives of fixed assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Revenues
Revenues
5639186 usd
us-gaap Profit Loss
ProfitLoss
-6244179 usd
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.73
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zjPH9ogzTU76" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_865_ziWCA3wweChj">Concentration of Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $<span id="xdx_902_eus-gaap--CashFDICInsuredAmount_iI_c20240930_zF16smzqGx25" title="Federal insured limit">250,000</span>. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flow.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
us-gaap Advertising Expense
AdvertisingExpense
232396 usd
us-gaap Advertising Expense
AdvertisingExpense
42947 usd
CY2024Q3 us-gaap Advertising Expense
AdvertisingExpense
101271 usd
CY2023Q3 us-gaap Advertising Expense
AdvertisingExpense
15206 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10326990 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5467061 shares
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7154429 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
319143 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2254486 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-60278 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2194208 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
43750 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1943 usd
CY2024Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
14583 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1943 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2350386 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
298484 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
7154429 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
319143 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1973864 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2294504 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6006892 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-5630823 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24417 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
5914 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-54392 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
85676 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1998281 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2288590 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6061284 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5545147 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2559 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2294 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11650 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
18700 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-2000840 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-2290884 usd
us-gaap Net Income Loss
NetIncomeLoss
-6072934 usd
us-gaap Net Income Loss
NetIncomeLoss
-5563847 usd
CY2024Q3 BIAF Patient Service Fees
PatientServiceFees
1119933 usd
CY2023Q4 BIAF Patient Service Fees
PatientServiceFees
657717 usd
CY2024Q3 BIAF Histology Fees
HistologyFees
151548 usd
CY2023Q4 BIAF Histology Fees
HistologyFees
121301 usd
CY2024Q3 BIAF Medical Director Fees
MedicalDirectorFees
6494 usd
CY2023Q4 BIAF Medical Director Fees
MedicalDirectorFees
3103 usd
CY2024Q3 us-gaap Other Receivables
OtherReceivables
49193 usd
CY2023Q4 us-gaap Other Receivables
OtherReceivables
29553 usd
CY2024Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
1327168 usd
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
811674 usd
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
275706 usd
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
171855 usd
CY2024Q3 BIAF Prepaid Legal And Professional
PrepaidLegalAndProfessional
10148 usd
CY2023Q4 BIAF Prepaid Legal And Professional
PrepaidLegalAndProfessional
24476 usd
CY2024Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
154173 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
124686 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
440027 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
321017 usd
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
911636 usd
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
831756 usd
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
493446 usd
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
373123 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
418190 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
458633 usd
us-gaap Depreciation
Depreciation
119526 usd
us-gaap Depreciation
Depreciation
66780 usd
CY2024Q3 us-gaap Depreciation
Depreciation
40472 usd
CY2023Q3 us-gaap Depreciation
Depreciation
45095 usd
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
659294 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
857037 usd
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
66361 usd
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
257926 usd
CY2024Q3 BIAF Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
135286 usd
CY2023Q4 BIAF Accrued Clinical Expense Current
AccruedClinicalExpenseCurrent
15350 usd
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
43311 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
19498 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
904252 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1149811 usd
CY2024Q3 us-gaap Deferred Revenue
DeferredRevenue
24404 usd
CY2023Q4 us-gaap Deferred Revenue
DeferredRevenue
33058 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
96243 usd
CY2023Q3 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
32081 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
288729 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
32081 usd
CY2024Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
21533 usd
CY2023Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
8634 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
67318 usd
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
8634 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
33198 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
9972 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
93029 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
9972 usd
CY2024Q3 us-gaap Lease Cost
LeaseCost
150974 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
50687 usd
us-gaap Lease Cost
LeaseCost
449076 usd
us-gaap Lease Cost
LeaseCost
50687 usd
CY2024Q3 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
91038 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
270143 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
8433 usd
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
203 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1235 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
493687 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
370312 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
124710 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
94708 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
375139 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
283001 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
1294168 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
1294168 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
417053 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
128324 usd
CY2024Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
877115 usd
CY2023Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
1165844 usd
CY2024Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
387780 usd
CY2023Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
365463 usd
CY2024Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
543007 usd
CY2023Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
835467 usd
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
930787 usd
CY2023Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
1200930 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y2M1D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y6M29D
CY2024Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y7M6D
CY2023Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0743 pure
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0807 pure
CY2024Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0802 pure
CY2023Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0801 pure
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
39341 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
112126 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
157837 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
448505 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
159282 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
270395 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
110063 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
202970 usd
CY2024Q3 BIAF Lessee Operating Lease Liability Payments Due Year Three And Thereafter
LesseeOperatingLeaseLiabilityPaymentsDueYearThreeAndThereafter
111788 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
578311 usd
CY2024Q3 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
1033996 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
78462 usd
CY2024Q3 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
103209 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
499849 usd
CY2024Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
930787 usd
CY2024Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
260000 usd
CY2024Q3 us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
24000 usd
CY2024Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.067 pure
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.007
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000 shares
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
185687 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
85245 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
755594 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
514313 usd
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
0 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
912446 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
28758 usd
us-gaap Adjustment Of Warrants Granted For Services
AdjustmentOfWarrantsGrantedForServices
72912 usd
CY2024Q3 BIAF Number Of Warrants Issued
NumberOfWarrantsIssued
11677147 shares
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.53
CY2024Q3 BIAF Number Of Warrants Exercised
NumberOfWarrantsExercised
-2103249 shares
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9573898 shares
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001493152-24-045954-index-headers.html Edgar Link pending
0001493152-24-045954-index.html Edgar Link pending
0001493152-24-045954.txt Edgar Link pending
0001493152-24-045954-xbrl.zip Edgar Link pending
biaf-20240930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
biaf-20240930_def.xml Edgar Link unprocessable
biaf-20240930_lab.xml Edgar Link unprocessable
biaf-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
biaf-20240930_cal.xml Edgar Link unprocessable